Chemotherapy-Associated Palmar-Plantar Erythrodysesthesia Syndrome

Abstract

Brief Reports1 December 1984Chemotherapy-Associated Palmar-Plantar Erythrodysesthesia SyndromeJOACOB J. LOKICH, M.D., CHERYL MOORE, R.N.JOACOB J. LOKICH, M.D., CHERYL MOORE, R.N.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-101-6-798 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe delivery of cancer chemotherapy by continuous infusion either for 5 days or for protracted durations has become common because of the substantial alleviation of toxicity, particularly acute gastrointestinal effects and cumulative drug effects (1). Short-term (120-hour or 5-day) infusions are commonly used for the delivery of fluorouracil (2), vinblastine (3), and doxorubicin (4). In a series of phase I and II trials of protracted infusion chemotherapy (5), we have seen an unusual dermatologic syndrome involving the palms and soles that limits the ability to continue treatment.A prodrome of dysesthesias develops in the palms and soles that is initially...References1. CARLSONSIKIC RB. Continuous infusion or bolus injection in cancer chemotherapy. Ann Inter Med. 1983;99:823-33. LinkGoogle Scholar2. SEIFERTBAKERREEDVAITKEVICIUS PHMV. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer. 1975;36:123-8. CrossrefMedlineGoogle Scholar3. YAPBLUMENSCHEINKEATINGHORTOBAGYITASHIMALOO HGMGCT. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep. 1980;64:279-83. MedlineGoogle Scholar4. LEGHABENJAMINMACKAY SRB. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1983;96:133-9. LinkGoogle Scholar5. LOKICHPERRIBOTHE JJA. Cancer chemotherapy via ambulatory infusion pump. Am J Clin Oncol. 1983;6:355-63. CrossrefMedlineGoogle Scholar6. DUNAGIN W. Clinical toxicity of chemotherapeutic agents: dermatologic toxicity. Semin Oncol. 1982;9:14-22. MedlineGoogle Scholar7. BURGDORFGILMOREGANICK WWR. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med. 1982;97:61-2. LinkGoogle Scholar8. DOYLEBERGBOTTINOCHABNER LCGB. Erythema and desquamation after high-dose methotrexate. Ann Intern Med. 1983;98:611-2. LinkGoogle Scholar9. VOGELZANGBOSLJOHNSONKENNEDY NGKB. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981;95:288-92. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New England Deaconess Hospital Harvard Medical School Boston, Massachusetts PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByReactive erythemaPerformance of capecitabine in novel combination therapies in colorectal cancerClinical and Pathologic Findings with Differential Diagnostic ListsReactive ErythemasReferences and Further ReadingManagement of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients' Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology CentersAcute Cancer Pain Syndromes in Palliative Care EmergenciesCutaneous toxicity of oral low-dose methotrexateAcute Cancer Pain Syndromes in Palliative Care EmergenciesErythrodysestesia-like skin eruption due to docetaxel with a nonimmediate positive intradermal skin test resultGestion des effets secondaires cutanés des chimiothérapies et thérapies cibléesLevofolene modulates apoptosis induced by 5-fluorouracil through autophagy inhibition: Clinical and occupational implicationsNeoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen studyEnhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemiaAntimetabolite ReactionsThe History of Supportive OncodermatologyProphylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: A meta-analysisToxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplantReactive ErythemaLiposomal drug delivery systems: From concept to clinical applicationsCapecitabine induced Hand–Foot Syndrome: Report of two casesDrug-induced Nail ChangesSíndrome mão-pé induzida por quimioterapia: relato de um casoReferences and Further ReadingCutaneous adverse reactions to drugsChemotherapy-induced iatrogenic injury of skin: New drugs and new conceptsThe emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapiesImpact of prophylactic pyridoxine on occurrence of hand–foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancerPHARMACOKINETICS: Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in chinese patients with breast tumo